0001836268-20-000005.txt : 20201218 0001836268-20-000005.hdr.sgml : 20201218 20201217182139 ACCESSION NUMBER: 0001836268-20-000005 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201217 EFFECTIVENESS DATE: 20201218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MitoChem Therapeutics, Inc. CENTRAL INDEX KEY: 0001836268 IRS NUMBER: 453845208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-383566 FILM NUMBER: 201397364 BUSINESS ADDRESS: STREET 1: 645 MEETING STREET CITY: CHARLESTON STATE: SC ZIP: 29403 BUSINESS PHONE: 520-204-5552 MAIL ADDRESS: STREET 1: 645 MEETING STREET CITY: CHARLESTON STATE: SC ZIP: 29403 D/A 1 primary_doc.xml X0708 D/A LIVE 0001836268 MitoChem Therapeutics, Inc. 645 MEETING STREET CHARLESTON SC SOUTH CAROLINA 29403 520-204-5552 DELAWARE None None Corporation true Michael Voevodsky c/o MitoChem Therapeutics, Inc. 645 Meeting Street Charleston SC SOUTH CAROLINA 29403 Executive Officer Director Rick G. Schnellman c/o MitoChem Therapeutics, Inc. 645 Meeting Street Charleston SC SOUTH CAROLINA 29403 Director Baerbel Rohrer c/o MitoChem Therapeutics, Inc. 645 Meeting Street Charleston SC SOUTH CAROLINA 29403 Director Gyda Caren Beeson c/o MitoChem Therapeutics, Inc. 645 Meeting Street Charleston SC SOUTH CAROLINA 29403 Director Biotechnology Decline to Disclose 06b true 0001836268-20-000002 2020-12-02 false true false 0 300000 235766 64234 false 7 0 0 0 Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering. false MitoChem Therapeutics, Inc. /s/ Michael Voevodsky Michael Voevodsky President and Chief Executive Officer 2020-12-17